Renal sympathetic denervation in patients with vasospastic angina
BACKGROUND: Sympathetic overactivity has been linked to vasospastic angina (VSA), although the exact pathophysiology of VSA is poorly understood. The purpose of this study is to assess if renal sympathetic denervation (RDN) reduces cardiac sympathetic nerve activity with a subsequent beneficial effect on angina relief in patients with refractory VSA.
METHODS AND RESULTS: Cardiac sympathetic nerve activity was assessed prior to procedure and at 6 months post-procedure using iodine-123 labeled meta-iodobenzylguanidine (123I-MIBG) imaging. The Seattle Angina questionnaire (SAQ) was used to assess the degree to which the disease impacts quality of life. No significant change was observed in early HMR (pre-RDN: 2.74 [2.10 to 3.21] vs 6 months post-RDN: 2.57 [2.20 to 3.00]; P = 0.76), and late HMR (pre-RDN: 2.56 [2.18 to 3.20] vs 6 months post-RDN: 2.36 [2.13 to 3.22]; P = 0.22). Additionally, no change was seen in WR (P = 0.22). SAQ results revealed significant improvements in perceived physical limitation, angina frequency, and quality of life at 6 months (P < 0.05 for all).
CONCLUSION: RDN resulted in improvements in angina class and quality of life at 6 months in patients with refractory VSA. RDN, however, did not result in significant changes in cardiac sympathetic nerve activity as measured using 123I-MIBG. The latter observation should be considered with caution given the small sample size of this study. Larger studies are needed to assess this further.
| Errataetall: |
CommentIn: J Nucl Cardiol. 2020 Dec;27(6):2210-2215. - PMID 30761479 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology - 27(2020), 6 vom: 13. Dez., Seite 2202-2209 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Feyz, Lida [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3-Iodobenzylguanidine |
|---|
| Anmerkungen: |
Date Completed 20.12.2021 Date Revised 30.01.2024 published: Print-Electronic CommentIn: J Nucl Cardiol. 2020 Dec;27(6):2210-2215. - PMID 30761479 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12350-019-01598-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM293870713 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM293870713 | ||
| 003 | DE-627 | ||
| 005 | 20240130231914.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12350-019-01598-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1275.xml |
| 035 | |a (DE-627)NLM293870713 | ||
| 035 | |a (NLM)30761478 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Feyz, Lida |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Renal sympathetic denervation in patients with vasospastic angina |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.12.2021 | ||
| 500 | |a Date Revised 30.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: J Nucl Cardiol. 2020 Dec;27(6):2210-2215. - PMID 30761479 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Sympathetic overactivity has been linked to vasospastic angina (VSA), although the exact pathophysiology of VSA is poorly understood. The purpose of this study is to assess if renal sympathetic denervation (RDN) reduces cardiac sympathetic nerve activity with a subsequent beneficial effect on angina relief in patients with refractory VSA | ||
| 520 | |a METHODS AND RESULTS: Cardiac sympathetic nerve activity was assessed prior to procedure and at 6 months post-procedure using iodine-123 labeled meta-iodobenzylguanidine (123I-MIBG) imaging. The Seattle Angina questionnaire (SAQ) was used to assess the degree to which the disease impacts quality of life. No significant change was observed in early HMR (pre-RDN: 2.74 [2.10 to 3.21] vs 6 months post-RDN: 2.57 [2.20 to 3.00]; P = 0.76), and late HMR (pre-RDN: 2.56 [2.18 to 3.20] vs 6 months post-RDN: 2.36 [2.13 to 3.22]; P = 0.22). Additionally, no change was seen in WR (P = 0.22). SAQ results revealed significant improvements in perceived physical limitation, angina frequency, and quality of life at 6 months (P < 0.05 for all) | ||
| 520 | |a CONCLUSION: RDN resulted in improvements in angina class and quality of life at 6 months in patients with refractory VSA. RDN, however, did not result in significant changes in cardiac sympathetic nerve activity as measured using 123I-MIBG. The latter observation should be considered with caution given the small sample size of this study. Larger studies are needed to assess this further | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a MIBG | |
| 650 | 4 | |a Renal sympathetic denervation | |
| 650 | 4 | |a meta-iodobenzylguanidine | |
| 650 | 4 | |a quality of life | |
| 650 | 4 | |a vasospastic angina | |
| 650 | 7 | |a 3-Iodobenzylguanidine |2 NLM | |
| 650 | 7 | |a 35MRW7B4AD |2 NLM | |
| 700 | 1 | |a Henneman, Maureen |e verfasserin |4 aut | |
| 700 | 1 | |a Verzijlbergen, Fred |e verfasserin |4 aut | |
| 700 | 1 | |a Kardys, Isabella |e verfasserin |4 aut | |
| 700 | 1 | |a Van Mieghem, Nicolas M |e verfasserin |4 aut | |
| 700 | 1 | |a Daemen, Joost |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology |d 1994 |g 27(2020), 6 vom: 13. Dez., Seite 2202-2209 |w (DE-627)NLM087703971 |x 1532-6551 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2020 |g number:6 |g day:13 |g month:12 |g pages:2202-2209 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12350-019-01598-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2020 |e 6 |b 13 |c 12 |h 2202-2209 | ||